| Index | — | P/E | 79.10 | EPS (ttm) | 0.68 | Insider Own | 3.65% | Shs Outstand | 217.61M | Perf Week | 0.45% |
| Market Cap | 11.70B | Forward P/E | 69.08 | EPS next Y | 0.78 | Insider Trans | -0.39% | Shs Float | 215.95M | Perf Month | 5.99% |
| Enterprise Value | 13.12B | PEG | — | EPS next Q | 0.15 | Short Float | 15.36% | Perf Quarter | -1.25% | ||
| Income | 122.00M | P/S | 4.68 | EPS this Y | 16.14% | Short Ratio | 11.21 | Perf Half Y | 7.30% | ||
| Sales | 2.50B | P/B | 3.13 | EPS next Y | 30.93% | ROA | 2.12% | Short Interest | 33.18M | Perf YTD | 14.30% |
| Book/sh | 17.20 | P/C | 74.55 | EPS next 5Y | — | ROE | 3.67% | 52W High | 58.70 -8.36% | Perf Year | 18.74% |
| Cash/sh | 0.72 | P/FCF | 44.68 | EPS past 3/5Y | — 66.63% | ROIC | 3.14% | 52W Low | 44.61 20.58% | Perf 3Y | — |
| Dividend Est. | 1.00 (1.86%) | EV/EBITDA | 28.70 | Sales past 3/5Y | 11.78% 13.78% | Gross Margin | 14.94% | Volatility | 3.58% 2.65% | Perf 5Y | — |
| Dividend TTM | 1.00 (1.86%) | EV/Sales | 5.24 | EPS Y/Y TTM | — | Oper. Margin | 6.74% | ATR (14) | 1.40 | Perf 10Y | — |
| Dividend Ex-Date | Sep 30, 2026 | Quick Ratio | 0.18 | Sales Y/Y TTM | 16.32% | Profit Margin | 4.84% | RSI (14) | 55.82 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 0.18 | EPS Q/Q | 166.67% | SMA20 | 2.73% | Beta | -0.04 | Target Price | 63.63 |
| Payout | 147.52% | Debt/Eq | 0.42 | Sales Q/Q | 24.13% | SMA50 | 1.25% | Rel Volume | 0.64 | Prev Close | 53.52 |
| Employees | 121 | LT Debt/Eq | 0.27 | Earnings | Nov 05 | SMA200 | 4.45% | Avg Volume | 3.15M | Price | 53.79 |
| IPO Date | Feb 07, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 16.64% 3.98% | Net Debt/EBITDA | 3.09 | Volume | 2,013,167 | Change | 0.50% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-13-26 | Initiated | Raymond James | Strong Buy | $62 |
| Oct-13-26 | Reiterated | Barclays | Overweight | $66 → $60 |
| Sep-14-26 | Reiterated | UBS | Buy | $63 → $65 |
| Sep-02-26 | Reiterated | Scotiabank | Sector Outperform | $47 → $62 |
| Aug-31-26 | Reiterated | Barclays | Overweight | $61 → $66 |
| Aug-19-26 | Reiterated | Keybanc | Overweight | $58 → $68 |
| Aug-14-26 | Reiterated | Truist Securities | Buy | $57 → $61 |
| Aug-14-26 | Reiterated | RBC Capital | Outperform | $56 → $61 |
| Jul-21-26 | Initiated | Compass Point | Buy | $70 |
| Jul-08-26 | Reiterated | UBS | Buy | $51 → $63 |
American Healthcare REIT (AHR) was forged through a significant strategic consolidation, combining Griffin-American Healthcare REIT III and Griffin-American Healthcare REIT IV, along with integrating the business and operations of American Healthcare Investors. This comprehensive merger has established AHR as a leading global real estate investment trust focused on healthcare properties, boasting an impressive portfolio with a gross investment value of approximately $4.2 billion. A core strength of the company lies in its fully integrated management platform, staffed by over one hundred highly experienced and proficient professionals. Many members of this team have a long history of collaboration, dating back to 2006, and have successfully invested in and overseen healthcare real estate assets across diverse market cycles. Their collective expertise, extensive industry network, and deep, firsthand understanding of each property within the international portfolio – which they have meticulously built and managed since its first acquisition in 2014 – are unparalleled. This powerful combination of a robust management team and a high-quality asset base strategically positions American Healthcare REIT to capitalize on compelling growth opportunities, driven by significant demographic trends. Its expansive portfolio encompasses 19 million square feet across 312 distinct properties, including medical office buildings, senior housing communities, skilled nursing facilities, and integrated senior health campuses. This diverse collection is strategically distributed across 36 U.S. states and the United Kingdom. The aforementioned tri-party transaction represented a pivotal step in ideally preparing American Healthcare REIT for a future public listing or Initial Public Offering (IPO) on a national stock exchange when market conditions are most favorable. By eventually listing its shares, the company anticipates gaining enhanced access to attractive capital sources, which will be crucial for fueling future expansion, diversifying its investor base, and providing greater liquidity for its existing stockholders. American Healthcare REIT, Inc. operates as a subsidiary of Griffin Capital Company, LLC.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,502 | 2,260 | 2,071 | 1,859 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 2,128 | 1,794 | 1,654 | 1,502 | — | — | — | — | — | |
| Gross Profit | 374 | 467 | 417 | 357 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 37,583 | 110 | 101 | 105 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | -37,378 | 188 | 179 | 175 | — | — | — | — | — | |
| Operating Income | 170 | 169 | 137 | 77 | — | — | — | — | — | |
| Interest Expense | 78 | 86 | 128 | 163 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 7 | -34 | -43 | 10 | — | — | — | — | — | |
| Net Income Before Taxes | 99 | 49 | -34 | -76 | — | — | — | — | — | |
| Income Taxes | -24 | -22 | 2 | 1 | — | — | — | — | — | |
| Consolidated Net Income | 122 | 70 | -38 | -71 | — | — | — | — | — | |
| Net Income From Continuing Operations | 123 | 71 | -36 | -77 | — | — | — | — | — | |
| Net Income | 122 | 70 | -38 | -71 | — | — | — | — | — | |
| EPS (Recurring) | 0.68 | 0.42 | -0.29 | -1.08 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.68 | 0.42 | -0.29 | -1.08 | — | — | — | — | — | |
| EPS (Diluted) | 0.68 | 0.42 | -0.29 | -1.08 | — | — | — | — | — | |
| EBITDA | 457 | 360 | 315 | 324 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 79.10 | 112.05 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.08 | 3.46 | 1.80 | — | — | — | — | — | — | |
| Gross Margin | 14.95 | 20.66 | 20.14 | 19.20 | — | — | — | — | — | |
| Operating Margin | 6.79 | 7.48 | 6.62 | 4.14 | — | — | — | — | — | |
| Net Margin | 4.88 | 3.10 | -1.83 | -3.82 | — | — | — | — | — | |
| Shares Outstanding | 190 | 166 | 131 | 66 | — | — | — | — | — | |
| Market Capitalization | 10,220 | 7,812 | 3,723 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Foster Mark E. | EVP, GC & Secretary | Sep 25 '26 | Sale | 52.06 | 1,500 | 78,090 | 50,117 | Sep 28 |
| Foster Mark E. | EVP, GC & Secretary | Sep 01 '26 | Sale | 55.39 | 2,000 | 110,780 | 51,617 | Sep 01 |
| Prosky Danny | Director | Jul 21 '26 | Option Exercise | 0.00 | 51,798 | 0 | 321,659 | Jul 22 |
| PEAY BRIAN | Chief Financial Officer | Jun 26 '26 | Sale | 50.70 | 25,000 | 1,267,403 | 152,700 | Jun 29 |
| Foster Mark E. | EVP, GC & Secretary | Jun 24 '26 | Sale | 48.58 | 2,500 | 121,450 | 52,995 | Jun 26 |
| Foster Mark E. | EVP, GC & Secretary | Apr 06 '26 | Option Exercise | 0.00 | 2,986 | 0 | 59,107 | Apr 08 |
| Oh Stefan K.L. | Chief Investment Officer | Apr 06 '26 | Option Exercise | 0.00 | 3,185 | 0 | 98,615 | Apr 08 |
| Willhite Gabriel M | Chief Operating Officer | Apr 06 '26 | Option Exercise | 0.00 | 6,768 | 0 | 151,819 | Apr 08 |
| PEAY BRIAN | Chief Financial Officer | Apr 06 '26 | Option Exercise | 0.00 | 6,768 | 0 | 181,354 | Apr 08 |
| Prosky Danny | Director | Apr 06 '26 | Option Exercise | 0.00 | 15,924 | 0 | 355,065 | Apr 08 |
| PEAY BRIAN | Chief Financial Officer | Mar 25 '26 | Option Exercise | 0.00 | 21,922 | 0 | 178,756 | Mar 27 |
| Foster Mark E. | EVP, GC & Secretary | Mar 25 '26 | Option Exercise | 0.00 | 11,108 | 0 | 60,100 | Mar 27 |
| Foster Mark E. | EVP, GC & Secretary | Mar 25 '26 | Sale | 48.55 | 2,000 | 97,100 | 56,121 | Mar 27 |
| Oh Stefan K.L. | Chief Investment Officer | Mar 25 '26 | Option Exercise | 0.00 | 14,237 | 0 | 98,018 | Mar 27 |
| Willhite Gabriel M | Chief Operating Officer | Mar 25 '26 | Option Exercise | 0.00 | 15,205 | 0 | 147,841 | Mar 27 |